These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35512013)

  • 1. Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates.
    Zhu DY; Gorman MJ; Yuan D; Yu J; Mercado NB; McMahan K; Borducchi EN; Lifton M; Liu J; Nampanya F; Patel S; Peter L; Tostanoski LH; Pessaint L; Van Ry A; Finneyfrock B; Velasco J; Teow E; Brown R; Cook A; Andersen H; Lewis MG; Lauffenburger DA; Barouch DH; Alter G
    PLoS Biol; 2022 May; 20(5):e3001609. PubMed ID: 35512013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
    Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
    mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous Ad26/Ad5 adenovirus-vectored vaccines elicited SARS-CoV-2-specific antibody responses with potent Fc activities.
    Klingler J; Kowdle S; Bandres JC; Emami-Gorizi R; Alvarez RA; Rao PG; Amanat F; Gleason C; Kleiner G; Simon V; Edelstein A; Perandones C; Upadhyay C; Lee B; Hioe CE
    Front Immunol; 2024; 15():1382619. PubMed ID: 38779671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern.
    Kitchin D; Richardson SI; van der Mescht MA; Motlou T; Mzindle N; Moyo-Gwete T; Makhado Z; Ayres F; Manamela NP; Spencer H; Lambson B; Oosthuysen B; Kaldine H; du Pisanie M; Mennen M; Skelem S; Williams N; Ntusi NAB; Burgers WA; Gray GG; Bekker LG; Boswell MT; Rossouw TM; Ueckermann V; Moore PL
    Cell Rep Med; 2022 Mar; 3(3):100535. PubMed ID: 35474744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques.
    Roozendaal R; Solforosi L; Stieh DJ; Serroyen J; Straetemans R; Dari A; Boulton M; Wegmann F; Rosendahl Huber SK; van der Lubbe JEM; Hendriks J; Le Gars M; Dekking L; Czapska-Casey DN; Guimera N; Janssen S; Tete S; Chandrashekar A; Mercado NB; Yu J; Koudstaal W; Perez-Ruixo JJ; Sadoff J; Barouch DH; Schuitemaker H; Zahn R
    Nat Commun; 2021 Oct; 12(1):5877. PubMed ID: 34620860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner.
    Keeton R; Richardson SI; Moyo-Gwete T; Hermanus T; Tincho MB; Benede N; Manamela NP; Baguma R; Makhado Z; Ngomti A; Motlou T; Mennen M; Chinhoyi L; Skelem S; Maboreke H; Doolabh D; Iranzadeh A; Otter AD; Brooks T; Noursadeghi M; Moon JC; Grifoni A; Weiskopf D; Sette A; Blackburn J; Hsiao NY; Williamson C; Riou C; Goga A; Garrett N; Bekker LG; Gray G; Ntusi NAB; Moore PL; Burgers WA
    Cell Host Microbe; 2021 Nov; 29(11):1611-1619.e5. PubMed ID: 34688376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination.
    Gorman MJ; Patel N; Guebre-Xabier M; Zhu AL; Atyeo C; Pullen KM; Loos C; Goez-Gazi Y; Carrion R; Tian JH; Yuan D; Bowman KA; Zhou B; Maciejewski S; McGrath ME; Logue J; Frieman MB; Montefiori D; Mann C; Schendel S; Amanat F; Krammer F; Saphire EO; Lauffenburger DA; Greene AM; Portnoff AD; Massare MJ; Ellingsworth L; Glenn G; Smith G; Alter G
    Cell Rep Med; 2021 Sep; 2(9):100405. PubMed ID: 34485950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
    Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
    Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.
    Francica JR; Flynn BJ; Foulds KE; Noe AT; Werner AP; Moore IN; Gagne M; Johnston TS; Tucker C; Davis RL; Flach B; O'Connell S; Andrew SF; Lamb E; Flebbe DR; Nurmukhambetova ST; Donaldson MM; Todd JM; Zhu AL; Atyeo C; Fischinger S; Gorman MJ; Shin S; Edara VV; Floyd K; Lai L; Boyoglu-Barnum S; Van De Wetering R; Tylor A; McCarthy E; Lecouturier V; Ruiz S; Berry C; Tibbitts T; Andersen H; Cook A; Dodson A; Pessaint L; Van Ry A; Koutsoukos M; Gutzeit C; Teng IT; Zhou T; Li D; Haynes BF; Kwong PD; McDermott A; Lewis MG; Fu TM; Chicz R; van der Most R; Corbett KS; Suthar MS; Alter G; Roederer M; Sullivan NJ; Douek DC; Graham BS; Casimiro D; Seder RA
    Sci Transl Med; 2021 Aug; 13(607):. PubMed ID: 34315825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques.
    Solforosi L; Costes LMM; Tolboom JTBM; McMahan K; Anioke T; Hope D; Murdza T; Sciacca M; Bouffard E; Barrett J; Wu C; Hachmann N; Miller J; Yu J; He X; Jacob-Dolan C; Huber SKR; Dekking L; Chamanza R; Choi Y; Boer KF; Barouch DH; Schuitemaker H; Zahn RC; Wegmann F
    Nat Commun; 2023 Apr; 14(1):1944. PubMed ID: 37029141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying Antibody Persistence After a Single Dose of COVID-19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach.
    Dari A; Boulton M; Neyens M; Le Gars M; Valenzuela B; Shukarev G; Cárdenas V; Ruiz-Guiñazú J; Sadoff J; Hoetelmans RMW; Ruixo JJP
    Clin Pharmacol Ther; 2023 Feb; 113(2):380-389. PubMed ID: 36377532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preserved recognition of Omicron spike following COVID-19 messenger RNA vaccination in pregnancy.
    Bartsch YC; Atyeo C; Kang J; Cai Y; Chen B; Gray KJ; Edlow AG; Alter G
    Am J Obstet Gynecol; 2022 Sep; 227(3):493.e1-493.e7. PubMed ID: 35430229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic Model Describing the Time Course of Humoral Immunity Following Ad26.COV2.S Vaccination in Non-Human Primates.
    Dari A; Solforosi L; Roozendaal R; Hoetelmans RMW; Pérez-Ruixo JJ; Boulton M
    J Pharmacol Exp Ther; 2023 Oct; 387(1):121-130. PubMed ID: 37536955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination.
    Gorman MJ; Patel N; Guebre-Xabier M; Zhu A; Atyeo C; Pullen KM; Loos C; Goez-Gazi Y; Carrion R; Tian JH; Yaun D; Bowman K; Zhou B; Maciejewski S; McGrath ME; Logue J; Frieman MB; Montefiori D; Mann C; Schendel S; Amanat F; Krammer F; Saphire EO; Lauffenburger D; Greene AM; Portnoff AD; Massare MJ; Ellingsworth L; Glenn G; Smith G; Alter G
    bioRxiv; 2021 Feb; ():. PubMed ID: 33564763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity.
    Richardson SI; Manamela NP; Motsoeneng BM; Kaldine H; Ayres F; Makhado Z; Mennen M; Skelem S; Williams N; Sullivan NJ; Misasi J; Gray GG; Bekker LG; Ueckermann V; Rossouw TM; Boswell MT; Ntusi NAB; Burgers WA; Moore PL
    Cell Rep Med; 2022 Feb; 3(2):100510. PubMed ID: 35233544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP.
    Solforosi L; Kuipers H; Jongeneelen M; Rosendahl Huber SK; van der Lubbe JEM; Dekking L; Czapska-Casey DN; Izquierdo Gil A; Baert MRM; Drijver J; Vaneman J; van Huizen E; Choi Y; Vreugdenhil J; Kroos S; de Wilde AH; Kourkouta E; Custers J; van der Vlugt R; Veldman D; Huizingh J; Kaszas K; Dalebout TJ; Myeni SK; Kikkert M; Snijder EJ; Barouch DH; Böszörményi KP; Stammes MA; Kondova I; Verschoor EJ; Verstrepen BE; Koopman G; Mooij P; Bogers WMJM; van Heerden M; Muchene L; Tolboom JTBM; Roozendaal R; Brandenburg B; Schuitemaker H; Wegmann F; Zahn RC
    J Exp Med; 2021 Jul; 218(7):. PubMed ID: 33909009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
    Sadoff J; Le Gars M; Brandenburg B; Cárdenas V; Shukarev G; Vaissiere N; Heerwegh D; Truyers C; de Groot AM; Jongeneelen M; Kaszas K; Tolboom J; Scheper G; Hendriks J; Ruiz-Guiñazú J; Struyf F; Van Hoof J; Douoguih M; Schuitemaker H
    Vaccine; 2022 Jul; 40(32):4403-4411. PubMed ID: 35667914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homologous and Heterologous Covid-19 Booster Vaccinations.
    Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
    N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
    Alleva DG; Delpero AR; Scully MM; Murikipudi S; Ragupathy R; Greaves EK; Sathiyaseelan T; Haworth JR; Shah NJ; Rao V; Nagre S; Lancaster TM; Webb SS; Jasa AI; Ronca SE; Green FM; Elyard HA; Yee J; Klein J; Karnes L; Sollie F; Zion TC
    Vaccine; 2021 Oct; 39(45):6601-6613. PubMed ID: 34642088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.